`
` Filed: August 24, 2016
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`IBG LLC; INTERACTIVE BROKERS LLC;
`TRADESTATION GROUP, INC.; TRADESTATION SECURITIES, INC.;
`TRADESTATION TECHNOLOGIES, INC.; and
`IBFX, INC.
`
`Petitioner
`v.
`
`
`
`
`
`
`
`
`
`
`
` TRADING TECHNOLOGIES INTERNATIONAL, INC.
`
`Patent Owner
`_________________
`Case CBM2015-00182
`U.S. Patent 6,772,132
`_________________
`
`PATENT OWNER’S REPLY IN SUPPORT OF ITS
`MOTION TO SUBMIT SUPPLEMENTAL INFORMATION AND
`BRIEFING UNDER 37 C.F.R. § 42.223(b)
`
`
`
`
`
`
`
`Case CBM2015-00182
`U.S. Patent 6,772,132
`Petitioners’ opposition makes clear that they erected their objections to TT’s
`
`
`
`use of the requested information under the district court PO simply as a roadblock.
`
`Rewarding such tactics would not serve the interests of justice. Instead, the
`
`interests of justice support allowing TT to submit these documents and briefing
`
`because the information supports TT’s positions on patent eligibility and
`
`nonobviousness, and is the most credible evidence from Petitioners.
`
`I.
`
`TT Was Not In A Position To Submit The Information Earlier
`
`TT was in no position to use this information before June 2016. TT did not
`
`have most of the information (6/8/16 and 6/9/16 Bartleman transcripts, 6/13/16
`
`Galik Transcript, Exhibits 2156, 2158, PDX 3046) before May/June of 2016.
`
`These documents were produced as a direct result of the district court’s order that
`
`certain discovery be completed for potential use in the PTAB. Ex. 2142.
`
`The three documents TT’s litigation counsel received at the end of 2015,
`
`(Exhibits 2143-2145) were produced by TS within over a hundred thousand pages
`
`of documents in the November/December 2015 time frame, which took months to
`
`cull to the relevant documents. Regardless, these documents were not authenticated
`
`until the depositions in June of 2016. And TT had no testimony on any of them,
`
`including PDX 3043 (TT webpage evidencing copying) until the June depositions.
`
`Thus, TT could not have gone to the district court with a list of what it
`
`sought to use in its Patent Owners Response (“POR”) until mid-June, when TT did
`
`
`
`1
`
`
`
`Case CBM2015-00182
`U.S. Patent 6,772,132
`just that. TT indeed withdrew its district court motion after Petitioners offered to
`
`“moot” it, but there was no obligation by TT to proceed on the same issue in two
`
`forums simultaneously (or in the district court first), and Petitioners’ “contrary”
`
`cases do not establish otherwise. For instance, the dispute in Meyer was whether
`
`Patent Owners’ could file a motion for additional discovery without violating the
`
`PO (absent Petitioners’ consent to discuss the documents therein, which TT had
`
`here). Likewise, both Daifuku and Electronic Frontier addressed whether litigation
`
`counsel could disclose confidential information to PTAB counsel under the
`
`litigation PO. Here, TT has always shared at least one litigation and PTAB counsel
`
`(Mr. Borsand) and thus there have never been such issues. Further, these non-
`
`precedential decisions contrast with other panels’ holdings that a district court PO
`
`does not bar the PTAB from ordering production. Cf. Chevron N. America, Inc. v.
`
`Milwaukee Elec. Tool Corp., IPR 2015-00595, Paper 31, at 4 (Oct. 30, 2015);
`
`Brunswick Corp. v. Cobalt Boats, LLC, IPR2015-01060, Paper 20 (Dec. 28, 2015).
`
`Petitioners’ opposition still provides no basis for their objections, but notes
`
`that they “reasonably exercised their right” under the PO.” Paper 88, at 4. This
`
`shows that Petitioners have never been concerned about any alleged sensitivity of
`
`the information, but needlessly blocked TT’s use to gain a strategic advantage. The
`
`record demonstrates TT’s diligent efforts to try to resolve the dispute without
`
`burdening this Board or the district court. For example, TT requested that TS
`
`
`
`2
`
`
`
`Case CBM2015-00182
`U.S. Patent 6,772,132
`approve of TT’s reliance on Exhibit 2144 (Matrix Requirements) on May 26, 2016,
`
`but TS refused to evaluate the request or confer until weeks later at the Bartleman
`
`depositions. Ex. 2397. On June 3, TT also sent a list of specific documents it
`
`sought to use (see Ex. 2399) and elaborated on how it would use the documents on
`
`June 8 (Ex. 2400). TT could not have relied on the information in this proceeding
`
`until the PO objections were resolved, which they now are.
`
`II. The Interests Of Justice Support That TT Be Able To Submit This
`Information and Supplemental Briefing
`
`The interests of justice dictate that this information be submitted and briefed
`
`as it strongly supports objective indicia and patent eligibility. While Petitioners
`
`argue that it is disputed whether MD_Trader embodies the claimed invention, this
`
`is not the case. The Federal Circuit recognized MD_Trader’s embodiment by the
`
`claimed invention, and TT’s POR provides claim charts from its expert, Chris
`
`Thomas, mapping the independent claims to MD_Trader. Ex. 2233; see also Ex.
`
`2169B, at ¶¶ 108-114 (further explaining how MD_Trader is embodied).
`
`Petitioners’ argument that TT is changing its theory midstream by arguing
`
`that Matrix and Booktrader are commercial embodiments of the claimed inventions
`
`similarly fails. TT’s POR shows widespread adoption of the invention by
`
`competitors (Paper 66, at 46) and provided Mr. Thomas’s claim charts mapping the
`
`claimed features to the Matrix and Booktrader products. Ex. 2233. Further, Mr.
`
`Thomas also explained public evidence of copying by Matrix. Id. at ¶¶ 115-121.
`3
`
`
`
`
`
`Case CBM2015-00182
`U.S. Patent 6,772,132
`Such evidence detailing copying and commercial success of products that embody
`
`the claimed invention is highly relevant to secondary considerations of
`
`nonobviousness. Gambro Lundia AB v. Baxter Healthcare Corp., 110 F.3d 1573,
`
`1579 (Fed. Cir. 1997) (finding commercial success and touting of advantages of
`
`infringing product, along with prominence of patented technology in ads
`
`“require[d] a holding of nonobviousness.”); see Brown & Williamson Tobacco
`
`Corp. v. Philip Morris Inc., 229 F.3d 1120, 1130 (Fed. Cir. 2000) (success of an
`
`infringing product is evidence of “commercial success of the claimed invention”).
`
`Petitioners also claim that TT has not shown a nexus between commercial
`
`success, copying, and the claimed features. This is not the case as detailed below
`
`and may also be inferred from the evidence. See Brown, 229 F.3d at 1130
`
`(inferring nexus between claims and commercial success due to the “prominence
`
`of the patented technology in [the infringer’s] advertising”).
`
`There is no prejudice or burden to Petitioners. TT’s proposed supplemental
`
`arguments do not take Petitioners by surprise: TT extensively identified relevant
`
`portions of the information along with its argument.
`
`A. Bartleman Transcripts, Exhibits 2144 and PDX 3043
`
`Mr. Bartleman’s testimony as TS’s CEO and former head of Product
`
`Management for the Matrix product contradicts Petitioners’ position that the
`
`claimed invention is not technological, but abstract. Further, when Bartleman’s
`
`
`
`4
`
`
`
`Case CBM2015-00182
`U.S. Patent 6,772,132
`testimony, Exhibit 2144, PDX 3043, and Mr. Thomas’ declaration are evaluated as
`
`a whole, they show that Mr. Bartleman
`
`
`
`
`
`
`
` Further support for nexus is detailed in Exhibit 2145 and in TT’s POR.
`
`B. Exhibits 2143, 2145, and PDX 3046
`
`TT did not quote from these exhibits due to the Board’s order. However,
`
`Exhibit 2145 touts the claimed features and resulting benefits. Exhibit 2143 shows
`
`that Matrix has become the
`
`, and PDX 3046 establishes
`
`that Matrix has
`
`
`
`. Taken together with Bartleman’s testimony and Mr.
`
`Thomas’ declaration, the touting of the claimed features in Exhibit 2145 supports
`
`the nexus between the claimed features and Matrix’s ultimate commercial success.
`
`C. Exhibits 2154, 2156, and 2158 (IB)
`
`Exhibits 2154 and 2158 support that the claimed GUIs are not abstract, but
`
`technological in nature as even IB’s CEO defined aesthetics in terms of the fonts
`
`and colors of GUIs, not their overall structure and makeup. Further, Exhibit 2156
`
`links the success of the claimed invention as a whole with its commercial success.
`
`Respectfully Submitted,
`
`By: /Rachel L. Emsley/
`Rachel L. Emsley, Reg. No. 63,558
`5
`
`
`
`Date: August 24, 2016
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Case CBM2015-00182
`U.S. Patent 6,772,132
`
`The undersigned hereby certifies that a copy of the foregoing PATENT
`
`OWNER’S REPLY IN SUPPORT OF ITS MOTION TO SUBMIT
`
`SUPPLEMENTAL INFORMATION AND BRIEFING UNDER 37 C.F.R. §
`
`42.223(b) was served on August 24, 2016, via email directed to the following
`
`counsel of record for the Petitioner:
`
`Robert Sokohl
`rsokohl-PTAB@skgf.com
`
`Lori Gordon
`lgordon-PTAB@skgf.com
`
`Richard Bemben
`rbemben-PTAB@skgf.com
`
`John C. Phillips
`CBM41919-0006CP1@fr.com
`
`PTAB@skgf.com
`
`
`
`Date: August 24, 2016
`
`
`
`
`
`
`
`
`
`
`
`/Valencia Daniel/
`Valencia Daniel
`Litigation Legal Assistant
`
`
`
`
`
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP